Synexus wins first contract to conduct ophthalmology studies
Synexus announced its plans to be involved in ophthalmology trials last October after discussions with leading sponsors. The trial will be conducted on behalf of a pharmaceutical company
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
The Wiley Protocol, the brainchild of Wiley, is a trademarked, patent-protected, bio-identical hormone replacement therapy (HRT) delivery system consisting of biomimetic estradiol and progesterone in a topical cream